GlassScriptPhysician profile
Sidney Charles Rubenstein
NPI 1518975283
$952.57
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $450 · 2021: $148 · 2022: $66.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $222.69 | 2019-2020 | |
| Teleflex LLC | $148.26 | 2021 | |
| Astellas Pharma US INC | $112.02 | 2019 | |
| Medtronic USA, INC. | $75.43 | 2020 | |
| Axonics, INC. | $69.50 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $67.31 | 2019 | |
| Boston Scientific Corporation | $60.22 | 2020 | |
| Janssen Biotech, INC. | $55.89 | 2019 | |
| Procept Biorobotics Corporation | $54.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $27.28 | 2019 | |
| Coloplast Corp | $20.96 | 2020 | |
| Metuchen Pharmaceuticals | $14.41 | 2020 | |
| Urogen Pharma, INC. | $12.01 | 2022 | |
| Allergan, INC. | $11.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Charles Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.